Jane Owen, a partner in the Middletons' Intellectual Property Group, speaks with David Bushby about the recent Federal Court decision in which French drug maker sanofi-aventis failed to stop the sale of a generic version of its mutli-million dollar cancer treatment, Taxotere.They discuss the ramifications of this case in the on-going battle between propriety pharmaceutical companies and generic drug manufacturers.

To listen to the radio interview, please click here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.